Scientist.com Launches Pharma Observatory, an Agent-First Market Intelligence Platform for Biopharma R&D
18.11.2026 13:55:00 CET | Business Wire | Press release
Puts every trial, drug, company, investigator and patent in one cross-referenced model, built for AI agents from day one, with simple published pricing
Scientist.com, the leading AI-enabled R&D orchestration platform and marketplace for the life science industry, today announced the launch of Pharma Observatory, a market intelligence platform that shows biopharma teams where their programs sit in the wider market. Scientist.com helps research teams drive a project forward. Pharma Observatory places that project in context: who else is working on the same target or indication, who the likely partners and acquirers are, and what the eventual clinical trials are likely to look like.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118907460/en/

Scientist.com's Pharma Observatory brings nearly 1 billion records from ~100 public sources (ClinicalTrials.gov, FDA, USPTO, NIH, SEC) into one cross-referenced model.
The public record on biopharma is huge but scattered. ClinicalTrials.gov, the FDA, SEC filings, PubMed, NIH, the USPTO and dozens of other sources each publish part of the picture, and each uses its own name for the same drug, company or physician. Pharma Observatory matches those records ahead of time. A drug filed under a code name, a generic name and a brand name becomes one page, with its trials, sponsors and patents attached. Figures link back to the registry entry, filing or publication they came from.
Broad by design
Pharma Observatory draws on approximately 100 data sources and nearly 1 billion source records. It covers more than 600,000 clinical trials, 370,000 investigators, 350,000 organizations, 1.1 million biomedical patents, 1 million funding events and 640,000 regulatory enforcement events. Trials, sites and investigators sit beside funding, ownership, patents and FDA enforcement history, so a question that runs from the clinic to the boardroom can be answered in one place.
Built for AI agents from the start
Pharma Observatory was designed for AI agents first, rather than having an API added after the fact. Its Model Context Protocol (MCP) server works with Claude, ChatGPT, Claude Code, Codex, Cursor and VS Code. A free public endpoint needs no account and no token, so a researcher can point an agent at it in under a minute. Paid plans unlock the full tool set, every row of data and a documented REST API. An agent can ask which sponsors are running Phase 2 trials in an indication, which sites have enrolled fastest in comparable studies, or which suppliers have FDA inspection history, and get back sourced answers it can reason over.
Simple, transparent pricing
Most competitive intelligence platforms sell through enterprise quotes behind a “Contact Us” form. Pharma Observatory publishes its prices and can be bought by card: $199 per seat per month for an Individual plan with a 14-day trial, or $299 per seat per month for a Team plan with single sign-on and directory sync. MCP and API access come with every paid plan. Enterprise and academic terms are available.
Who it is for
Pharma Observatory serves the teams that need to understand the market around a program: business development and licensing, clinical operations and feasibility, competitive intelligence, medical affairs, quality and supplier risk, life-science investors, and the contract research organizations and service providers that support them.
The same data works from the supplier side of the market. Scientist.com already uses Pharma Observatory to build growth intelligence reports for the CROs, labs and service providers on its marketplace, showing each one which sponsors are running trials in its specialty, which programs are moving into stages that need its services, and where recent funding points to new demand. Because trials, funding rounds, patents and regulatory events sit in one cross-referenced model, the platform also surfaces industry trends as they form: which targets and modalities are drawing investment, which indications are seeing a rise in new trials, and where activity is shifting between regions.
“Scientist.com has spent years helping researchers move their projects forward. Pharma Observatory answers the question that comes right before that and keeps coming back: where does this project sit in the market?” said Chris Petersen, Co-founder and CTO of Scientist.com. “We built it for agents from the first line of code, because that is how our customers’ research teams increasingly work. An agent should be able to ask about competitors, partners and trial design and get an answer it can trace to a source.”
Pharma Observatory is available today at pharmaobservatory.com. Free condition and biomarker pages and the public MCP endpoint need no account.
About Scientist.com
Scientist.com is a leading AI-enabled R&D orchestration platform and marketplace for the life sciences industry. It connects researchers with a global network of more than 6,000 qualified scientific suppliers and provides integrated tools for sourcing, competitive bidding, contracting, compliance, and procurement. Scientist.com powers secure, private marketplaces for leading pharmaceutical companies and hundreds of biotech firms, supporting outsourced R&D from discovery through clinical research. Headquartered in Solana Beach, California, the company serves research organizations and suppliers worldwide. Learn more at www.scientist.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261118907460/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Yonder Announces New Leadership18.11.2026 14:03:00 CET | Press release
CTO Salil Joshi Named Interim CEO to Lead Next Phase of Growth with Accelerated Innovation and Expanded Use of Company’s Technology Blue Yonder, the AI company for supply chain, today announced that Salil Joshi has been named interim Chief Executive Officer. Joshi has most recently served as Blue Yonder’s Chief Technology Officer, where he led the company’s technology vision and growth strategy across the digital supply chain. Joshi succeeds Duncan Angove, who will transition out of the CEO role after four years leading the company. The Blue Yonder Board appreciates the contributions that Angove has made to the company. “Blue Yonder continues to showcase strong momentum through accelerating Cognitive Solutions adoption in the market. Blue Yonder has reported impressive SaaS ARR growth, adding new customer logos and increasing inclusions in key tech and industry analyst reports,” said Ken Sain, Chairman of the Blue Yonder Board of Directors and CEO of Panasonic Connect Group. “We believ
AI Private Markets Platform FinBursa Appoints Angelica Tigan as Chief Revenue Officer to Drive US and Global Growth18.11.2026 14:00:00 CET | Press release
Former BlackRock and eFront sales leader joins the agentic AI front office FinBursa, the intelligent front office for private markets, has appointed Angelica Tigan, a former BlackRock and eFront sales leader, as Chief Revenue Officer to lead its global commercial expansion following the launch of FinBursa 360. Based in the US, Tigan will lead sales and partnerships worldwide, with an immediate focus on the US. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118596329/en/ Angelica Tigan, based in New York City, joins FinBursa as Chief Revenue Officer Tigan brings close to two decades in private markets technology, having built, led and scaled sales teams at BlackRock (Aladdin) and eFront, with previous experience at Intralinks and Gen II Fund Services. FinBursa 360 is an all-in-one platform for private equity, private credit, real estate, venture capital and M&A advisory firms, family offices, wealth managers, placement age
Helical Fusion Awarded Up to JPY 19.2 Billion in Japanese Government Funding to Accelerate Commercial Fusion Power18.11.2026 13:36:00 CET | Press release
Bringing together Japan’s fusion research and manufacturing expertise to advance commercial fusion Helical Fusion Co., Ltd., a fusion energy company developing commercially viable power plants based on Helical Stellarator technology, has been formally selected for a major Japanese government grant program administered by the Ministry of Economy, Trade and Industry (METI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118128278/en/ The maximum government subsidy is approximately JPY 19.2 billion (USD 126 million). The grant-supported project is scheduled to run through February 2029. Through the Helix Program, Helical Fusion leads overall plant design and systems integration, drawing on research from Japan’s national research institutions and the engineering and manufacturing expertise of approximately 40 companies in Japan. The program aims to turn Japan’s scientific and industrial strengths into practical fusion power.
Grand Prix ACF AutoTech 2027: Applications Open for the 10th Edition18.11.2026 13:00:00 CET | Press release
Since 2018, the competition’s 52 finalists have raised more than €700 million The Automobile Club de France (ACF) and ESSEC Alumni are launching the 10th edition of the Grand Prix ACF AutoTech, the leading competition for automotive and mobility startups. French and international startups can apply until November 27, 2026 at 11:59 p.m. (CET) at www.grandprixacfautotech.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118772168/en/ Jury members and former finalist startups for the launch of 10th Edition of Grand Prix ACF AutoTech (c) Quentin Vaquez Since 2018, the competition has selected 52 finalists, including Chargemap, Hiflow, ChargeGuru and Geolith, who have together raised more than €700 million. Only 6 have failed: a survival rate of nearly 90%. The 2026 edition rewarded Altrove (Grand Prix ACF), Bloomineral (ACF Pioneer Prize and GreenTech Mention) and IoT.bzh (Industrialization Prize). “Ten editions is an achie
New TOURISE Report Reveals How Traveler Expectations Are Changing the Rules for Global Tourism18.11.2026 13:00:00 CET | Press release
Report urges tourism leaders to focus on high-value trips, not just high-spending visitors, and measure benefits retained by local communities Nearly 150 million more households could afford international leisure travel by 2030, including almost 110 million in Asia Pacific 59% of surveyed AI users turn to AI for travel information, but only 12% of consumers in a separate survey trust it to make decisions independently 43% of travelers surveyed across 35 markets planned to avoid overcrowded destinations in 2026 Changing traveler priorities are reshaping global tourism, influencing where people go, how they spend and what they value most from their journeys. A new report released by TOURISE, The Future Traveller, explores these shifts and what they mean for the industry through 2030. Developed in collaboration with Euromonitor International, the report draws on consumer surveys and perspectives from industry leaders. The report finds that travel decisions are increasingly shaped by the p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom